Ultrasound-Guided Stellate Ganglion Block for Alzheimer's Disease
Status:
COMPLETED
Trial end date:
2025-11-29
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn if ultrasound-guided stellate ganglion block (SGB), added to standard drug treatment, can improve thinking and memory in people with Alzheimer's disease. It will also learn about the safety of SGB.
The main questions this study aims to answer are:
Do people who receive SGB plus standard drug treatment have better global cognition, measured by the Mini-Mental State Examination (MMSE), 1 month after finishing the treatment course compared with people who receive standard drug treatment alone? How do anxiety, depression, quality of life, and ability to live independently change over 1 month, 3 months, and 6 months after treatment? What medical problems, if any, occur during or after SGB?
Researchers will compare two groups:
SGB plus standard drug treatment Standard drug treatment alone
Participants will:
Be randomly assigned to one of the two groups Receive the assigned treatment Complete study visits and assessments at baseline and at 1 month, 3 months, and 6 months after finishing the treatment course
Phase:
NA
Details
Lead Sponsor:
Taizhou Second People's Hospital
Collaborator:
Taizhou Municipal Bureau of Science and Technology